Skip to content
Agentic OS
Menu

Intelligence / Healthtech / PMA Approvals / Medtronic, INC.

Approvalsdevice change approved (PMA)10 Sept 2026

Medtronic, INC.

10 Sept 2026: Device change approved (PMA) · Symplicity Spyral™ Renal Denervation System. Recorded in the openFDA device PMA data.

View the source record

Decided
10 Sept 2026
Device
Symplicity Spyral™ Renal Denervation System
Specialty
Cardiovascular
Type
Supplement (Normal 180 Day Track No User Fee)
Reason
Labeling Change - PAS
Reference
P220026 S014
Location
Santa Rosa, CA
What this signal means

A PMA approval is a high-risk device launch: reimbursement, distribution, clinical training and sales hires follow.

  1. Cardiovascular leads with 53 of 120, then Pathology (15).
  2. 35 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Medtronic, INC.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Medtronic, INC. in our registers.

More in Cardiovascular

PMA Approvals

See all

Source: openFDA device PMA data, data to 18 Nov 2026. Class III devices approved by FDA: original approvals and supplements that change the device (180-day, panel-track and special tracks). 30-day manufacturing notices are left out. AOS shows what the public record says; it does not verify or endorse the company.